Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.

MLA

Huang, Pei-Yu, et al. “Expression of EIF5A2 Associates with Poor Survival of Nasopharyngeal Carcinoma Patients Treated with Induction Chemotherapy.” BMC Cancer, vol. 16, Aug. 2016, p. 669. EBSCOhost, https://doi.org/10.1186/s12885-016-2714-2.

APA

Huang, P.-Y., Zeng, T.-T., Ban, X., Li, M.-Q., Zhang, B.-Z., Zhu, Y.-H., Hua, W.-F., Mai, H.-Q., Zhang, L., Guan, X.-Y., & Li, Y. (2016). Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. BMC Cancer, 16, 669. https://doi.org/10.1186/s12885-016-2714-2

Chicago

Huang, Pei-Yu, Ting-Ting Zeng, Xiaojiao Ban, Meng-Qing Li, Bao-Zhu Zhang, Ying-Hui Zhu, Wen-Feng Hua, et al. 2016. “Expression of EIF5A2 Associates with Poor Survival of Nasopharyngeal Carcinoma Patients Treated with Induction Chemotherapy.” BMC Cancer 16 (August): 669. doi:10.1186/s12885-016-2714-2.